The global budesonide inhaler market is expected to grow at a significant CAGR during the forecast period (2021-2027). Budesonide is a corticosteroid drug that is used for the prevention and treatment of various symptoms including coughing, wheezing, chest tightness, and shortness of breath caused due to asthma and chronic obstructive pulmonary disease (COPD). This medication directly acts on the lungs and reduces the swelling and irritation of the airways to treat asthma and COPD-like conditions.
A full report of Budesonide Inhaler Market is available at: https://www.omrglobal.com/industry-reports/budesonide-inhaler-market
The increasing demand for efficient treatment for various respiratory diseases including asthma, COPD, nasal congestion, and others is anticipated to propel the demand for budesonide inhalers and drive its market growth during the forecast period. The growing prevalence of asthma disease and other breathing problems due to the increasing rate of air pollution across the globe is further expected to elevate the need for budesonide inhalers, as preventive medicine for such health care conditions. This factor will contribute significantly to the growth of the global budesonide inhaler market during the forecast period. The growing number of patients suffering from respiratory diseases and the requirement for long-term treatment is creating new opportunities for the budesonide inhaler in the market across the globe. Additionally, the rising number of launches in generic versions of budesonide inhalers is further projected to witness lucrative growth opportunities for the global budesonide inhaler market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/budesonide-inhaler-market
The global budesonide inhaler market includes some of the key vendors including AstraZeneca, Cosmo Pharmaceuticals, Teva Pharmaceuticals, among others. To maintain a strong position in the market, these market players are adopting various strategies that include product launches, partnerships and collaborations, technological advancement, and mergers and acquisitions. For instance, in July 2020, AstraZeneca announced the FDA approval of Breztri Aerosphere, a combinational drug of budesonide/glycopyrrolate/formoterol used for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered- By Distribution Channel, By Dosage, By Product Type
- Regions Covered- Globally
- Competitive Landscape- AstraZeneca, Cosmo Pharmaceuticals, Teva Pharmaceuticals, Pfizer, Mylan, Orion Corporation, Lupin Limited, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Budesonide Inhaler Market by Segment
By Product Type
- Inhalants
- Nebulizers
By Dosage
- Aerosols
- Dry Powder
- Spray
- Suspension
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
